THERAPEUTIC GOODS AMENDMENT (2009 MEASURES NO.2) BILL 2009
THE INQUIRY
1.1
On 25 June 2009 the Senate, on the recommendation of the Selection of
Bills Committee (Report No.10 of 2009), referred the Therapeutic Goods
Amendment (2009 Measures No.2) Bill 2009 to the Community Affairs Legislation
Committee for inquiry and report by 7 August 2009.
1.2
The Committee received 9 submissions relating to the Bill and these are
listed at Appendix 1. The Committee considered the Bill at a public hearing in
Canberra on 8 July 2009. Details of the public hearing are referred to in
Appendix 2. The submissions and Hansard transcript of evidence may be accessed
through the Committee's website at https://www.aph.gov.au/senate_ca/.
BACKGROUND
1.3
The National Competition Policy Review of Drugs, Poisons and Controlled
Substances was announced in July 1999. The Review, conducted by Ms Rhonda
Galbally, examined State and Territory legislation that imposed controls in
Australia on supply and use of drugs, poisons and controlled substances against
the Principles of National Competition Policy.
1.4
A number of proposals for national uniformity of regulations through
legislative reforms were made by the Review, with recommendations for change in
the areas of increasing national uniformity, improving efficiency, reducing the
level of control where possible, and improving the net benefit to the community
as a whole of those controls which rely on professional practice to be
effectual.
1.5
The Final Report of the Galbally Review was presented to the Australian
Health Ministers' Conference (AHMC) in January 2001. A Working Party of the
Australian Health Ministers' Advisory Council prepared a response to the
Galbally Review recommendations in April 2003 which was approved by the Council
of Australian Governments (COAG) in June 2005. The Working Party had also taken
account of the proposal to establish an Australia New Zealand Therapeutic
Products Authority (ANZTPA) so that the Review recommendations should be implemented
on a trans-Tasman basis.
1.6
The National Coordinating Committee on Therapeutic Goods (NCCTG)
oversighted the implementation of the Galbally Review recommendations, most of
which were implemented in 2006-07. However, with the suspension of negotiations
to establish the proposed ANZTPA in July 2007, the NCCTG proceeded to implement
the remaining Review recommendations on an Australia-only basis.[1]
1.7
A key recommendation from the Galbally Review was to provide separate
scheduling arrangements for medicines and chemicals to reflect the different
uses and environments in which these substances are made available and used. A
2008 Productivity Commission Research Report on Chemicals and Plastics
Regulation supported the Review by recommending that new scheduling arrangements
be implemented as soon as feasible.
1.8
The Minister's second reading speech describes the scheduling process:
Scheduling is a collaborative process involving both the Commonwealth
and the states and territories. A committee established under Commonwealth law
with state and territory representatives makes decisions that are then
implemented through state and territory legislation.
Scheduling is the process by which substances that can be
harmful if not used or kept correctly are grouped into categories, known as
schedules. Specific requirements are then attached to the schedules under state
and territory law regarding supply, availability and oversight of use to
support the safe and effective use of these substances. This then has a flow-on
effect on the supply, availability and use of medicines and chemicals that
contain scheduled substances.
Scheduling decisions are recorded in a document known as the
Poisons Standard[2],
which brings together the names and details of the substances that have been
scheduled and categorises these by schedule. The Poisons Standard is
principally used by the states and territories as a tool for regulating public
access to and availability of medicines, veterinary, agricultural and domestic
chemicals.[3]
THE BILL
1.9
The scheduling amendments in Schedule 1 of the Bill implement the
outstanding Review recommendations that were deferred with the suspension of
the ANZTPA negotiations. The Explanatory Memorandum notes that 'these
amendments reflect extensive consultation with industry and other interested
parties'.
1.10
The Bill provides for the replacement of the existing National Drugs and
Poisons Scheduling Committee (NDPSC) that makes scheduling decisions with two
new expert advisory committees, which will provide recommendations and advice
to the Secretary of the Department of Health and Ageing to inform the Secretary
in making scheduling decisions.
1.11
The new Advisory Committee on Medicines Scheduling will be able to
provide recommendations and advice about substances used in medicines, while
the new Advisory Committee on Chemicals Scheduling will advise on substances
such as agricultural, domestic and veterinary chemicals.
1.12
Decisions of the Secretary will then be incorporated into the Poisons
Standard. This will be retained as a single complete reference for the
scheduling classifications of both medicinal and chemical substances.
1.13
One key element from the existing scheduling arrangements will be
retained - the cooperative arrangement the Commonwealth has with the states and
territories. This is necessary under the Constitution to achieve scheduling
implementation uniformly across all states and territories. Reflecting this
important collaborative Commonwealth-state/territory arrangement for scheduling,
the advisory committees will include members from the Commonwealth and each of
the states and territories as well as other experts to be provided for in the
subordinate legislation.
1.14
Transitional provisions will ensure that applications currently under
consideration by the NDPSC are able to be transferred across for consideration
under the new arrangements and that any recommendations made by that committee
will be taken into account by the Secretary. This is intended to ensure a
smooth transition to the new arrangements upon their commencement on 1 July
2010. The commencement date will also provide time for the development of
supporting subordinate legislation.
1.15
Schedule 2 of the Bill will enable the Secretary to declare purposes for
which kinds of medical devices cannot be included in the Australian Register of
Therapeutic Goods. Purposes will be precluded where such a use would pose a
risk to public health or where it would be otherwise inappropriate.[4]
1.16
Schedule 3 contains a number of amendments including provisions that
will:
-
enable the TGA to consult with and seek advice from the Gene
Technology Regulator about applications for the listing or registration of
therapeutic goods that are genetically modified organisms or that contain GMOs;
-
clarify inappropriate advertising of therapeutic goods to ensure
that appropriate, consistent and accurate information is provided to the public
to support the safe and effective use of therapeutic goods; and
-
improve the transparency of the requirements for advisory
statements on medicine labels by empowering the Minister to specify them in a
legislative instrument. These statements assist consumers in choosing the most
appropriate medicine and using it safely and effectively as the medicines these
statements apply to are generally those which individuals choose themselves or
with the assistance of a pharmacist.
1.17
The Minister's second reading speech advises that:
The government intends to make further changes to the
therapeutic goods regulatory regime later in the year. In particular, we intend
to introduce further legislation to give effect to a new framework for the regulation
of human cellular and tissue based therapies, as foreshadowed as part of the
ANZTPA process.[5]
ISSUES
1.18
There was general support for the principles underlying the Bill,
especially the separation of medicines and chemicals scheduling; however the
support was conditional. The Complementary Healthcare Council (CHC) noted that
many of the amendments 'are long overdue and welcomed by the complementary
healthcare industry'. The CHC, 'in general, supports the principles within the
Bill however has some concerns relating to several of the proposals'.[6]
The Australian Self-Medication Industry (ASMI) similarly considered 'that the Bill
represents some important progress and we offer support for it... However, we
have serious reservations about the lack of transparency and accountability of
the process set out in the Bill.[7]
ACCORD also raised a 'number of important questions' that required answers
'before we would be in a position to unequivocally endorse the passage of the
Bill as written'.[8]
Consultation
1.19
Industry groups advised that they had been involved in the many
processes following the Galbally Review and had provided submissions on the
discussion papers produced in recent years. However they were scathing at their
treatment and the outcomes. ASMI stated that 'throughout all that time, the
Government’s consultations have been far from extensive or meaningful' and, in
proposing amendments to improve the Bill, commented that 'if we had been
consulted in a meaningful way, perhaps some of our proposals might have already
been in the Bill'. ASMI provided a list of the occasions that they provided
submissions over the past decade and asserted:
In every case, Governments have not engaged in any discussion
with us and, in many respects, our reasoned arguments have been rejected or
ignored without explanation or further discussion.[9]
1.20
ACCORD expressed similar experiences:
At a process level, ACCORD is perturbed that the Senate is
now in a position of having to review and consider technical policy matters
that should ideally have been instead subject to more effective stakeholder
consultation by the Therapeutic Goods Administration. This is especially
the case considering the number of detailed submissions our organisation has
made previously to the TGA on this matter.[10]
1.21
Industry groups were also critical of the lack of feedback. ACCORD
summed up this criticism stating that:
A major problem with the consultation processes has been the
lack of formal feedback to, or engagement with, chemical industry stakeholder
groups. ACCORD has never received any official feedback from the TGA in
relation to either our 2005 or 2007 submissions.
Put bluntly, ACCORD and the broader chemicals industry have
been 'left in the dark' for several years now on the details of the likely
policy arrangements for chemicals scheduling... For this reason, industry has at
various times in this long-running process, had to resort to writing to the
Prime Minister and/or other senior Government ministers seeking their
intervention to improve the process of agency-level engagement with chemical
stakeholders.[11]
1.22
The Pharmaceutical Society of Australia (PSA) also experienced some
difficulty in tracking progress and outcomes of the various consultations, asserting
that 'this has been due to lack of feedback on our submissions, long periods
where there appears to be low level (or no) activity, ‘low-key’ announcements
of outcomes, or follow-up consultations where the outcomes are more or less
determined with little or no scope for change.[12]
1.23
The Department's submission constantly reiterated that 'extensive
consultation' was undertaken in the development of the Galbally Review
recommendations and the proposed scheduling changes and that consultation
comments on earlier drafts of documents had 'been taken into account in the
development of the latest drafts'. At the hearing, the Department described
three main phases in the consultative process and noted that a response to the
2005 consultation was on the website, there was 'not an outcome summary or
feedback loop' for the 2006 consultation involving ANZTPA because ANZTPA was
not proceeded with and in relation to the May 2009 consultation period 'any
time soon the NCCTG should be authorising us to put a document on the website
saying what people said and what our reaction to that was'.
Our general proposition is that if people have responded to
the call for submissions on the consultation documents we will put a document
on the website saying ,’This is what we decided in relation to each of those
things,’ and saying why.[13]
1.24
Industry clearly does not regard this as a satisfactory approach to
consultation by the Department. The Committee is concerned that the issue of
consultative processes used by the Department has been the subject of critical
comment in a number of recent inquiries. ASMI encapsulated this concern when it
said that 'industry does not accept that a take it or leave it approach amounts
to meaningful consultation'.
The two Advisory Committees
Administrative framework
1.25
While the intention to separate the medicines and chemicals scheduling
committees was supported, there was significant questioning as to whether the
planned administrative framework was appropriate. Industry considered that it would
be more suitable for the Chemicals Scheduling Committee to be administered by
another body where chemical safety evaluation, for substances not intended to
be used in therapeutic goods, is conducted as part of their current function.
1.26
The argument is that the TGA’s role is to assess and monitor activities
to ensure therapeutic goods available in Australia are of an acceptable
standard; assessments and evaluation of substances that are not intended for
the purpose of therapeutic goods should be the responsibility of another, more
relevant, department or body.
1.27
ACCORD especially emphasised this issue stating that 'the housing of
chemicals scheduling within a non-chemical regulator, the TGA, is an entirely
inappropriate administrative arrangement for the goal of establishing a more
efficient, nationally integrated system of chemicals regulation'. For ACCORD:
The key problem is that the measures introduced through this
bill place chemicals scheduling in the medicines agency, and therefore further
away in both a policy and an administrative sense from NICNAS, the Office of
Chemical Safety and Environmental Health, the APVMA, the soon-to-be established
standing committee on chemicals and the proposed national environmental
chemicals bureau. That is why we consider this to be a retrograde step.[14]
1.28
ACCORD indicated that they had recently been advised by government that:
The legislative approach being adopted through this Bill is
preferred because it avoids the need for new state and territory legislation.
Our understanding of this position is that creation, at this
point in time, of a separate legislative approach to underpin chemicals
scheduling would entail significant delays in achieving a separation of
chemicals scheduling from medicines scheduling.
This is conditionally accepted, but still leaves our industry
with a dilemma.[15]
1.29
The Department noted that the establishment of two committees while
maintaining one Poisons Standard recognised the close relationship between
medicines and chemicals, as some substances may be used in both medicinal and
chemical products, eg antibiotics, steroids and essential oils. DoHA responded
to the ACCORD position in their submission stating that:
Establishing the two committees under different acts would be
problematic as the AHMC agreed model would require both committees to be
responsible for amending the same legislative instrument – the Poisons
Standard. It would be problematic for two Acts to have responsibility and
control over the same instrument. (The states and territories have made it
clear through the NCCTG that the single scheduling standard must be retained to
allow appropriate reference in their respective legislation).[16]
1.30
Indeed the successful implementation of this scheme relies on the
States' continued support as confirmed by the Department at the hearing:
...it has been very clear from AHMC downwards that the states
will only countenance this if they do not have to change their legislation to
refer to chemicals and medicines standards.[17]
1.31
ACCORD did not dispute that this was the position of State and Territory
governments on this matter, though they viewed 'such intransigent demands to
maintain status quo or follow a path of least effort as unhelpful for improving
national productivity'. However, ACCORD did dispute the Department's portrayal
of their position as reflected in the above quote, advising that 'while we have
consistently argued for our preferred position of separate legislation for
chemicals scheduling, we have also proposed administrative alternatives to
achieve the policy goal for a more workable separation'.[18]
1.32
ACCORD did respond to the issue of overlap when products could be used
in both medicinal and chemical products:
In my view that is a furphy that has been promulgated to
justify a singular committee for some time. Really, what chemicals and
medicines scheduling is about is intended use. The committee would routinely
specify the intended use: whether it is for a medicine or for chemical or
household consumer use. This is clear in the current standard—the differential
intended use. So the hazard of a chemical is not going to change regardless of
its intended use, but its risk management—what concentrations you would allow
as a cosmetic and what concentrations you would allow in therapeutic use—would
change depending on the intended use. So it should be the intended use that
drives this.[19]
1.33
Some industry groups suggested that chemicals scheduling would more
appropriately sit within the Office of Chemical Safety and Environmental Health
(OCSEH), because this would better integrate it with the overall chemical
management and also keep it within the Department of Health.[20]
ACCORD regards chemical scheduling as a public health issue that should be
under the Department of Health, just not in the medicines agency. In supporting
OCSEH ACCORD noted:
Ms Capanna – Indeed they offer the current secretariat
for the National Drugs and Poisons Schedule Committee, recognising that there
are elements under the current system, which is joint medicines and chemicals
scheduling. The office of chemical safety recognises that and deals with the
Therapeutic Goods Administration, NICNAS as the industrial chemicals regulator
and indeed the APVMA as the agvet regulator.
Mr Brock - Further, it deals with new and emerging
issues. It would be looking at issues such as nanotechnology, which is a new
issue coming up in the chemicals area; it will be looking at issues of security
sensitive chemicals, and that is being run out of the Attorney-General’s
Department; and it will most likely interact with the environment agencies and
the Environment Protection and Heritage Council proposal for a new
environmental chemicals bureau. So there is a lot happening in chemicals
regulation and, to put this key part of the chemical regulatory framework into
the TGA, we think removes a possibility for greater integration and national
coordination.[21]
1.34
The Department advised that the OCSEH would be involved, explaining that
it was the intention for the delegate for medicines decisions to reside within
the TGA while the delegate for chemicals decisions would reside within OCSEH.
These administrative arrangements are contained within the Scheduling Policy
Framework.
The expectation is the medicine scheduling power will be
devolved to the TGA and the chemical scheduling power will be devolved to the
office of chemical safety. The intention is to have a common secretariat for
the advisory committees within the TGA. The reason for that is to facilitate
exchange of information between the two committees and also, frankly, it will
be cheaper for the industry if we have one committee rather than two.[22]
Legal validity
1.35
ACCORD raised the issue of the legal validity of the proposal, arguing
that, at a more fundamental level, 'the legal validity of housing chemicals scheduling
in the unrelated Therapeutic Goods Administration is also unclear. This especially
relates to future plans by this agency to implement industry cost-recovery arrangements'.
For this reason, ACCORD commissioned independent legal advice from Mr Ian
Cunliffe whose opinion supported the general concerns held by industry over the
Bill. The legal opinion made four key conclusions:
-
Extending
the reach of the Therapeutic Goods Act to chemicals regulation will only
exacerbate inherent weaknesses in the constitutional underpinnings of this Act.
-
"..
.in light of reasons articulated by the High Court this month in Pape v
Commissioner of Taxation ...it is doubted whether provisions establishing the
Advisory Committee on Chemicals Scheduling and empowering the Secretary of the
Commonwealth Department of Health and Ageing to create a Schedule of Chemical
Substances are Constitutionally valid."
-
"The
Bill would apparently achieve a scheme for the regulation of chemicals across
Australia including implementing industry cost-recovery arrangements. Most of
this is invisible in the Bill itself. The substance is apparently to be
supplied by a combination of regulations, by State and Territory laws and by
extension of existing provisions of the TG Act to the new field of general chemical
regulation. While that is (subject to what I have said above) probably lawful,
its appropriateness as a legislative technique is doubtful. "
-
"As
ACCORD has submitted, it is not clear at all from the Bill how industry
cost-recovery arrangements would be established under the Bill. (Undesirably)
in relation to therapeutic goods, cost-recovery arrangements are largely the
creation of the TG Regulations...However the therapeutic goods regulatory
regime is characterised by requirements that products be registered or listed.
Charges are imposed by reference to registration/listing - either initial or continuing.
That will presumably not be the case with chemicals - or will it? Has anybody thought
it through? If so, why has the proposed approach not been articulated? Or will
it be done by regulations devised subsequent to passage of the Bill?"[23]
1.36
ACCORD considered that the legal opinion reinforced the industry's
policy concerns 'that the arrangements put in place by this Bill, in relation
to chemicals scheduling, are inappropriate and represent a retrograde step in
terms of the overarching COAG policy goal of creating a more efficient,
nationally integrated chemicals regulation system'. ACCORD doubted 'that any
workable system of TGA cost-recovery for chemicals scheduling would be able to
be legally underpinned, without resorting to administratively nonsensical
approaches' and concluded that:
The arrangements the Bill puts in place for chemicals
scheduling should be seen only as interim measures that are subject
to review two years after commencement, as recommended by the Productivity
Commission in its 2008 Chemicals and Plastics Regulation Research Report.
And that these interim measures be eventually replaced
by more appropriate federally controlled arrangements, outside the control of
the Therapeutic Goods Administration, but still within the Health Department
portfolio, in order to better integrate chemicals scheduling within a
more efficient, nationally integrated system of chemicals regulation.[24]
1.37
The Department responded to the legal validity issue:
First of all, chemical scheduling already takes place under
the Therapeutic Goods Act. The act sets out as one of its objectives in
paragraph 4(1)(b) is:
- (b) to provide a framework for the States and Territories to
adopt a uniform approach to control the availability and accessibility, and
ensure the safe handling, of poisons in Australia.
It then defines a poison as including anything in the poison
standard. On that point, I should also say that during the drafting of schedule
1 a number of issues emerged where we sought advice from the Australian
Government Solicitor and they did not raise any qualms at all about the legal
validity of what we were proposing. The Australian Government Solicitor are not
shy about pointing out where they think things are not going to work and they
did not have any qualms whatsoever.
I guess the third matter is that the Australian Government
Solicitor also observed that having two separate pieces of legislation amending
the one poisons standard would raise a whole lot of interesting and novel legal
issues and that they did not think that was a very helpful way to proceed.[25]
1.38
The Department thought that the question on legal validity had assumed
that the amendments confer power upon the TGA to make chemical scheduling
decisions. The Department advised that this is not correct: the amendments in
the bill confer power upon the Secretary of the Department, not upon the TGA.
The Secretary for administrative convenience may delegate her power to any
officer in the Department. As noted earlier it is the intention that scheduling
decisions on medicines will be delegated to the TGA; and decisions on chemicals
will be delegated to the Office of Chemical Safety.[26]
Constitution of the Advisory
Committees
1.39
The Bill provides that the Advisory Committees will be constituted in
accordance with the regulations and that the Commonwealth, each State and
Territory are each entitled to nominate a member. It was proposed that a
representative from the industry sector should be on the Committees. The CHC
argued that to ensure that substances used in complementary medicines are
assessed and evaluated appropriately, there should be appropriate complementary
medicine representation and expertise on the Medicines Scheduling Committee.[27]
1.40
ASMI also raised questions about the likely membership of the Medicines
Scheduling Committee, and, of fundamental importance, whether State bureaucrats
would continue to have a power of veto over all its decisions. ASMI considered:
That the jurisdictional members [of the current committee] have
displayed an unduly risk-averse approach to issues before them and have, on
occasion, voted in accordance with State-specific Ministerial priorities as
directed by them.
We consider it is essential that the regulations do not
continue this veto arrangement.[28]
1.41
ASMI also believed that the Committee should have an independent Chair,
that is not be ex officio a TGA officer, or an official of the Department of
Health and Ageing. They explained that expertise was needed at the committee
table and that was currently lacking. It 'is not to say TGA does not have
competence in this area; it is simply to say there are other skills that good
governance would demand be part of the process'.[29]
1.42
ACCORD raised similar issues on the membership of the Chemicals
Scheduling Committee. They questioned what provisions would ensure that the
States and Territories nominate members with appropriate expertise to ensure
the scientific integrity of the Chemicals Committee's decisions and why the
membership provisions remained silent on other key member bodies with both a
role and expertise in chemicals regulation for public health - NICNAS, APVMA
and DoHA's Office of Chemical Safety and Environmental Health.[30]
1.43
The Department explained the expertise that it envisaged for the
Committees, focussing on CHC's comment of complementary medicines expertise on
the Medical Scheduling Committee:
We want to have an expert committee. The sorts of things we
want the secretary to be advised about are things like toxicology and
pharmakinetics. The toxicology of complementary medicines is the same as the
toxicology of anything else, and so is the pharmakinetics, so we do not see
this committee as one to have complementary medicine expertise,
over-the-counter expertise, prescription medicine expertise and so on... So it is
more about scientific expertise that would cover a whole range of medicines.
That is what we see the committee membership being.[31]
Use of terms 'Medicines' and
'Chemicals'
1.44
The PSA noted that the draft Scheduling Policy Framework used the terms
'medicines' and 'poisons', though the Bill used the term 'chemicals' in place
of 'poisons'. They regarded this as 'somewhat confusing' and inconsistent use
of terminology.[32]
1.45
The Department clarified this change in terminology, advising that:
The term ‘chemicals’ is used in relation to the title of the
advisory committee, and that title was chosen because our colleagues from
ACCORD and others expressed concern that we were referring to their products as
being poisons rather than chemicals. In terms of the poisons standard, it is
still the poisons standard, as it always has been...[The explanatory memorandum] uses
the term ‘chemicals’ when it is referring to the chemicals committee and it
uses the word ‘poisons’ when it is referring to the poisons standard or,
indeed, the generic group of things that are medicines and chemicals.[33]
National uniformity
1.46
A major and ongoing issue of concern for industry groups has been the
variability in the implementation of scheduling and other related matters in
the States and Territories following a decision or recommendation made at a
national level.
1.47
ASMI argued 'that the 'uniform' scheduling system is only almost
uniform'. They considered that this is because the States have often not quite
legislated in accordance with the 'uniform' Schedule. These variations are
regarded as small and idiosyncratic and, in ASMI's view, not based on sound
principles. However, it was argued that these small variations are costly and
time-consuming for industry and contribute to situations which are not conducive
for the promotion of quality use of medicines principles.
1.48
ASMI noted that section 52AA of the Bill promises “a uniform system in
Australia” but the Scheduling Framework paper makes it clear that each State
and Territory will continue to reserve its position. PSA believed that
continuing to allow such flexibility has the potential to significantly
undermine the principles of quality use of medicines across Australia.[34]
1.49
The industry groups were strongly of the view that as a highest priority
the Commonwealth must ensure that uniformity in scheduling was complete across
all jurisdictions.
Powers of Secretary
1.50
The PSA noted that the revised list of factors which the Secretary must
take into account in exercising powers, subsection 52E(1), no longer includes
the safety of a substance, the patterns of use of a substance and the need for
(access to) a substance. The PSA commented:
It is PSA’s belief that these three factors, in addition to
those already proposed, are all fundamental considerations in the decision-making
process for the scheduling of a substance and therefore warrant their explicit
inclusion. The three issues referred to above are also mentioned in the
Scheduling Policy Framework as factors to be considered in a scheduling
decision and therefore their inclusion in the Bill will promote consistency
with the Framework.[35]
1.51
The Department advised that when the subsection was redrafted,
addressing the factors became repetitive:
What we are now saying is that we must have regard to the
risks and benefits of use; the purposes and extent of use; toxicity, dosage
formulation, labelling, packaging and presentation; the abuse potential; and
anything else. The PSA are saying that we should have regard to: safety—our
view is that ‘the risks and benefits’ covers that; the patterns of use—our view
is that ‘the purposes for which a substance is to be used and the extent of
use’ effectively covers that; and the need for access to a substance—again,
that comes under ‘the purposes for which a substance is to be used’. So we
think those criteria are actually covered.[36]
1.52
ASMI believed 'that the arrangements for delegated legislation as set
out in the Bill could be greatly improved', though it was particularly
concerned that subsection 52E(2) provided that the Secretary 'must comply' with
any guidelines of AHMAC or its subcommittee, the National Coordinating
Committee on Therapeutic Goods (NCCTG). ASMI submitted that as a non-elected
body, whose processes are not transparent, and whose members are not publicly
accountable, this subcommittee was an inappropriate body to issue binding
policy directions under ss 52E(2), particularly as the directions as set out in
the Scheduling Policy Framework are not proposed to be issued as a Legislative
Instrument.[37]
1.53
The Department responded to these concerns that the NCCTG was not
transparent or accountable:
Firstly, it is no different to what happens now...It is not
making a change. Secondly, the secret guidelines are the ones we have just been
consulting on. If they were really going to be secret we would not have.
Thirdly, for the most of the last three months I [Mr Maskell-Knight] have, for
my sins, been the acting chair of the [NCCTG]. In that capacity I have received
two requests for the committee to give guidance to the National Drugs and
Poisons Scheduling Committee, and they have both been from industry saying,
‘Why won’t you tell the National Drugs and Poisons Scheduling Committee to do
what industry wants?’ So there is a capacity for it to be a double-edged sword,
I would argue.[38]
1.54
ASMI provided drafting instructions for proposed amendments (reproduced
at Appendix 3) to address these issues and others referred to in this report
thereby improving the Bill. They believed that the proposed amendments were
'consistent with modern principles of transparency and accountability in
regulatory design'.[39]
1.55
ACCORD commented on the proposed amendments indicating that 'for the
most part these appear to be targeted at improving the accountability and
transparency of the operation of the scheduling committees' and that on this
basis, 'the suggestions relating to this aspect would be supported by ACCORD'. However,
they also reiterated their recommendation for a 2-year review and the eventual implementation
of more appropriate, separate arrangements for chemicals scheduling.[40]
1.56
The Department advised that they were willing to consider ASMI's
proposals, though some may not require a legislative response:
I think there are some issues with the drafting of a number
of [the ASMI proposed amendments] and I do not think they necessarily require
legislation. But there are some issues in there that we will think about.[41]
Cost recovery
1.57
Industry groups also raised concerns about the cost recovery proposals. The
CHC was concerned as to whether the complementary medicines industry was going
to be required to pay for chemical scheduling now separately to medicine
scheduling, especially as their existing fees and charges paid to the TGA have
significantly increased.[42]
However, as ASMI noted, the paper setting out proposed arrangements has not yet
been published and it is therefore unable to comment in significant detail.[43]
1.58
The Department confirmed that the current intention is to release a
draft cost recovery impact statement that will spell out a schedule of fees for
products listed under both the medicines and chemicals schedules. The
Department explained that:
The Therapeutic Goods Administration works on cost recovery
at the moment. There were suggestions that we do not want to be
cross-subsidising chemicals and so on. We do our very best to make sure that
each activity we undertake is covered by the fees we charge for that particular
activity. We have greater or lesser success with that, but those greater or
lesser successes are at the margin. We certainly do not intend that the
chemical industry will be getting a free ride from the therapeutic goods
industry, nor do we want the chemical industry to be paying more than its fair
share.[44]
Advertising offences for
inappropriate advertising
1.59
Industry recognised that inappropriate advertising of therapeutic goods
is of great concern, particularly in relation to accurate information being
provided to consumers. The proposed amendment in Schedule 3 will mean that
offence provisions can be applied to any persons found to be inappropriately
advertising a therapeutic good, not just sponsors as is the case now.
1.60
The CHC acknowledged this amendment will deter sponsors from recruiting
other persons to inappropriately advertise a product on their behalf, knowing
that they cannot be penalised. However, the CHC sought further clarification as
to how and when this provision would apply as they believed there may be
certain scenarios where this may be difficult to administer, eg there may be scenarios
where advertisements are published in good faith but are subsequently considered
to be an offence under the Act. The CHC also sought clarification of a defence
for an offence under this section and suggested that if the current wording in
the proposal is to remain, a defence should be included to cover any scenarios
where an advertisement is published in good faith.[45]
1.61
The CHC noted that it is currently working on an Advertising Reform
proposal; and that advertising had been identified by the previous
Parliamentary Secretary for Health and Ageing as an area requiring overall
review, to which the industry agrees. The CHC understood that the TGA is also
looking at advertising reform and suggested that any changes to the Act
relating to advertising be postponed until that review has been completed.[46]
ASMI did not support this suggestion, commenting that 'as part of a proper
review of advertising, it may come up again to be looked at, but it should not
hold up the passage of this work'.[47]
1.62
The Department confirmed that that they are 'working towards producing a
consultation document about how we think the advertising regime can be
simplified and improved' though that process should not delay this amendment.
...I think that this is a discrete problem that we have at the
moment and that we should not wait 12 months to fix it up. If you go online,
Senator, you will be able to find lots of online pharmacies bruiting products
completely outside the indications that are on the register for them. At the
moment there is no provision—there is nothing we can point to—that says, ‘Thou
shalt not do this because it is a criminal offence.’[48]
1.63
In relation to CHC's concern about advertising in good faith, the
Department did not consider that this was an issue because the DPP was highly
unlikely to form the view that it was in the public interest to prosecute
someone for publishing in the scenario provided and even if that were to
happen, the prosecuted person could use as a defence section 9.1 of the
Criminal Code Act relating to acting in a mistaken belief about or are ignorant
of particular facts.[49]
Advisory statements for medicines
1.64
The CHC referred to the amendments in Schedule 3, Part 2 of the Bill
relating to advisory statements for medicines and sought clarification as to
whether this proposal intends to alter the current process for establishing
these statements and whether the complementary medicine industry will continue
to be included in such consultations. The CHC indicated that it 'supports the
requirement of advisory statements (where needed) for medicines, including complementary
medicines, to inform consumers and raise awareness; however the CHC would like reassurance
that the processes in establishing these will be done in full consultation with
the complementary medicines industry'.[50]
1.65
ASMI also expected that there would be 'full and meaningful'
consultation on the legislative instrument to be made under these amendments.
ASMI proposed that a new sub-section 3(5C) be added to ensure that the legislative
instrument 'must not require sponsors of the therapeutic goods to affix labels
if the information would be misleading or deceptive, as those terms are used in
s52 of the Trade Practices Act'.[51]
1.66
In response to these issues relating to advisory statements the
Department provided the reassurance that was sought, confirming that 'they will
be disallowable', adding that 'the Legislative Instruments Act mandates you
must consult on legislative instruments, and we do consult on [Required Advisory
Statements for Medicine Labels] at the moment. We will continue to consult in
exactly the same way.'[52]
CONCLUSION
1.67
As is becoming common in recent times the Committee has once again been
asked to inquire into a Bill which provides for much of the detail on its
operation and administration to be outlined in yet to be drafted legislative
instruments. This Bill does not commence until 1 July 2010 specifically to
enable time for the associated regulations to be drafted. The Department has
indicated that certain regulations and guidelines will be released in draft
format and that industry will be involved prior to their finalisation.
1.68
The Committee considers that there remains a need for the Department and
industry to work constructively together through a number of areas where
industry raised concerns, and which will be the subject of legislative
instruments, including membership and expertise on the Scheduling Committees,
chemicals scheduling, appeal and review of decisions by the Secretary, cost
recovery and the publication of advisory statements.
1.69
The Committee is mindful of the Minister's comment in the second reading
speech that further changes to the therapeutic goods regulatory regime will be
made later in the year which reinforces the importance for government and
industry to work constructively together.
1.70
The Committee notes that the Department indicated that it considered
that some of the ASMI proposals for improved transparency and accountability
did not require a legislative response and that the other proposals would be
considered. The Committee requests that the Department provide both the
Committee and ASMI with feedback as to what actions it takes on these proposals
together with an explanation of its decisions.
1.71
The Committee heard from all sectors of industry that they had issues
with the Department's previous approach to consultation. It was not that there
had been a lack of consultation, rather that it lacked meaningful feedback to
explain why decisions had been reached and whether their proposals had been
considered and rejected or simply ignored. While expressing certain cynicism as
to the likelihood of continuing in this manner, the industry groups emphasised
that they still wished to engage and work with the Department to ensure the
best possible outcomes not just for these scheduling amendments but for the
regulation of therapeutic products, medicines and chemicals in general.
1.72
The Committee has concluded that the government should give a commitment
that it will undertake the further consultation as foreshadowed with industry
in a renewed sprit of openness and cooperation that will provide meaningful
feedback to the proposals, issues and general concerns held by industry to
ensure that the new system when fully implemented is supported by all parties
and is totally transparent and accountable.
1.73
The bottom line with these changes to scheduling and related matters is
to reduce risk and improve public health outcomes for the whole nation. The
Committee supports the Bill and considers that it should be passed without
delay to ensure that the maximum amount of time is available for the drafting
and consultative processes that will be required in the production of the
associated legislative instruments.
Recommendation
1.74
The Committee recommends that, subject to an undertaking by government
to actively pursue the issues raised in the Conclusion to implement this new
system, the Therapeutic Goods Amendment (2009 Measures No.2) Bill 2009 be
passed.
Senator
Claire Moore
Chair
August 2009
Navigation: Previous Page | Contents | Next Page